Duration of voriconazole exposure: An independent risk factor for skin cancer after lung transplantation

Dermatologic Surgery

Volumn 38, Issue 8, 2012, Pages 1369-1374

  Zwald, Fiona O ^a,b   Spratt, Margaret ^a   Lemos, Bianca D ^a   Veledar, Emir ^a   Lawrence, Clint ^a,b   Marshall Lyon, George ^a,b   Chen, Suephy C ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE;

ADULT; AGED; ARTICLE; CANCER RISK; DRUG EXPOSURE; FEMALE; HEALTH SURVEY; HUMAN; INFECTION PREVENTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYCOSIS; NONMELANOMA SKIN CANCER; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SKIN CANCER; SUN EXPOSURE; TREATMENT DURATION;

ANTIFUNGAL AGENTS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MYCOSES; PYRIMIDINES; RISK FACTORS; SKIN NEOPLASMS; TRIAZOLES;

EID: 84864581441     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2012.02418.x     Document Type: Article

References (12)

1. Husain S,. Unique characteristics of fungal infections in lung transplant recipients. Clin Chest Med 2009; 30: 307-13.
2. Minari A, Husni R, Avery RK, Longworth DL, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002; 4: 195-200. (Pubitemid 36142805)
3. Denning D, Griffiths C,. Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole. Clin Exp Dermatol 2001; 26: 648-53. (Pubitemid 33070418)
4. Cowen EC, Nguyen JC, Miller DD, McShane D, et al. Chronic Phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermato 2010; 62 (1): 31-7.
5. McCarthy K, Playford EG, Looke DF, Whitby M,. Severe photosentivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 2007; 44: 55-6.
6. VFEND (voriconazole) [package insert]. Pfizer, Inc: New York, NY, 2010;pp. 32.
7. Vanacker A, Fabré G, Van Dorpe J, Peetermans WE, et al. Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient. Am J Transplant 2008; 8: 877-80. (Pubitemid 351347751)
8. Brunel AS, Fraisse T, Lechiche C, Pinzani V, Mauboussin JM,. Multifocal squamous cell carcinomas in an HIV-infected patient with a long-term voriconazole therapy. AIDS 2008; 22: 905-6. (Pubitemid 351563843)
9. Feist A, Osborne SL, Thistlethwaite PA, Madani M, et al. Voriconazole use increases the incidence of skin cancer in lung transplant recipients (abstract). J Heart Lung Transplant 2009; 28: S242.
10. Miller D, Cowen EW, Nguyen JC, McCalmont TH, et al. Melanoma associated with long-term voriconazole therapy. Arch Dermatol 2010; 146 (3): 300-4.
11. Vadnerkar A, Nguyen MH, Mitsani D, Crespo M, et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant 2010; 29 (11): 1240-4.
12. Christie JD, Edwards LB, Kucheryavaya AY, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report-2008. J Heart Lung Transplant 2008; 27: 957-69.